Staedtisches Klinikum Dresden

The trials here

What the 25 trials at this site are about, from their registry records.

Conditions

• Psoriatic arthritis4 trials
• Deep vein thrombosis and pulmonary embolism3 trials
• Lupus (SLE)3 trials
• Psoriasis3 trials
• Bladder cancer2 trials
• Coronary artery disease2 trials
• Gastric and oesophageal cancer2 trials
• Giant cell arteritis2 trials
• Head and neck cancer2 trials
• Heart failure2 trials
• Peripheral artery disease2 trials
• Rheumatoid arthritis2 trials
• and 12 more

Phase

• Phase 317 trials
• Phase 24 trials
• Phase 2/32 trials
• Phase 1/21 trial
• Phase 41 trial

Status

• Completed9 trials
• Recruiting8 trials
• Active, not recruiting6 trials
• Not yet recruiting2 trials

Lead sponsor

• Anthos Therapeutics, Inc.2 trials
• Hoffmann-La Roche2 trials
• MoonLake Immunotherapeutics AG2 trials
• Novartis Pharmaceuticals2 trials
• Takeda2 trials
• and 15 more

Running trials

• Recruiting

  Early TRIPLE versus dual LIPID lowering treatment in peOple with atherosclerotic cardiovascular disease and hypercholesterolemia Undergoing elecTive revascularisation

  2026-525917-29-00· Phase 4· Medical University Of Graz· Source

• Recruiting

  Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

  NCT07318610· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis

  NCT07620392· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

  NCT07286058· Phase 3· Takeda· Source

• Recruiting

  A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

  NCT07201129· Phase 3· Viatris Innovation GmbH· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have not Responded to or who Cannot Tolerate TNF and/or JAK Inhibitors

  2025-521034-28-00· Phase 2· F. Hoffmann-La Roche AG· Source

• Recruiting

  Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC.

  2024-516906-47-00· Phase 2/3· Daiichi Sankyo Inc.· Source

• Active, not recruiting

  A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in participants aged 18 years and over with active psoriatic arthritis and antiTNFα inadequate response.

  2024-516219-25-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Active, not recruiting

  A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs

  2024-516213-20-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Active, not recruiting

  A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

  NCT06671483· Phase 3· Takeda· Source

• Recruiting

  FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

  NCT06788990· Phase 2/3· Bicara Therapeutics· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  NCT06330064· Phase 1/2· Daiichi Sankyo· Source

• Active, not recruiting

  Pulmonary Embolism International THrOmbolysis Study-3

  NCT04430569· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Active, not recruiting

  Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

  NCT04877691· Phase 3· AstraZeneca· Source

• Recruiting

  HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)

  NCT04447352· Phase 3· Krankenhaus Nordwest· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

  NCT04221477· Phase 3· Hoffmann-La Roche· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Head and neck cancer2 recruiting
• Peripheral artery disease2 recruiting
• Rheumatoid arthritis2 recruiting
• Cervical cancer1 recruiting
• Colorectal cancer1 recruiting
• Coronary artery disease1 recruiting
• Endometrial cancer1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lupus (SLE)1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting

Closed trials

• Completed

  A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction

  2023-508736-62-00· Phase 2· Cardurion Pharmaceuticals Inc.· Source

• Completed

  Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)

  NCT06215586· Phase 2· Cardurion Pharmaceuticals, Inc.· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Completed

  Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission

  NCT05380453· Phase 3· Novartis Pharmaceuticals· Source

• Terminated

  A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

  NCT05171075· Phase 3· Anthos Therapeutics, Inc.· Source

• Terminated

  A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

  NCT05171049· Phase 3· Anthos Therapeutics, Inc.· Source

• Completed

  Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

  NCT04930094· Phase 3· Novartis Pharmaceuticals· Source